17 August 2020 - The National Institute for Health and Care Excellence has now published final guidance backing NHS use of Astellas' Xospata as monotherapy for adults with relapsed or refractory FLT3 mutation-positive acute myeloid leukaemia (AML).

The endorsement remains contingent on the confidential commercial agreement agreed with the company, and does not include its use as a maintenance therapy after haematopoietic stem cell transplant.

Each year around 3,100 people in the UK are diagnosed with AML, a rare and aggressive cancer of the blood and bone marrow that, if untreated, can be fatal within a few months.

Read Pharma Times article